The Medicines Co. Plans Mid-2013 Regulatory Submissions For Two Key R&D Assets
This article was originally published in The Pink Sheet Daily
Executive Summary
The Medicines Co is capitalizing on trends prevalent in both the biopharma industry and its customer base to build one of the fastest- growing specialty pharma franchises. Results for 2012 confirm the strategy has worked to date.